



12 April 2021

**Incanthera plc**

**("Incanthera" or the "Company")**

**Result of General Meeting**

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the results of a General Meeting held at 11am today, in accordance with COVID-19 guidance.

The General Meeting follows the company's announcement on 23 March 2021, of a Placing to raise £1.14m, including an option for Warrants, which were subject to Shareholder approval.

The Company is pleased to announce that all resolutions were duly passed.

The Company would like to thank all Shareholders who returned their Proxy form and wishes all Shareholders and their families well.

**For further enquiries:**

**Incanthera plc**

[www.incanthera.com](http://www.incanthera.com)

**Tim McCarthy, Chairman**

[tim.mccarthy@incanthera.com](mailto:tim.mccarthy@incanthera.com)

+44 (0) 7831 675747

**Simon Ward, Chief Executive Officer**

[simon.ward@incanthera.com](mailto:simon.ward@incanthera.com)

+44 (0) 7747 625506

**Suzanne Brocks, Head of Communications**

[suzanne.brocks@incanthera.com](mailto:suzanne.brocks@incanthera.com)

+44 (0) 7776 234600

**Aquis Exchange Corporate Adviser:**

**Cairn Financial Advisers LLP**

Jo Turner/James Lewis

+44 (0) 20 7213 0880

**Broker:**

**Stanford Capital Partners Ltd**

Patrick Claridge/John Howes/Bob Pountney

+44 (0) 20 3815 8880

**Notes to Editors**

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to

current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: [www.incanthera.com](http://www.incanthera.com)